24 October 2019 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background/aim: Ticagrelor is a drug widely used in patients with acute coronary syndromes (ACS) that specifically increases the plasma level of adenosine, which is likely to cause atrial fibrillation (AF). Therefore, in this study we aimed to investigate the electrocardiographic and echocardiographic predictors of AF development after P2Y12 receptor antagonists in ACS patients. Materials and methods: This cross-sectional study included 831 patients with ACS (486 [58.5%] with ST elevated myocardial infarction [STEMI] and 345 [41.5%] with non-ST elevated myocardial infarction [NSTEMI]). Patients were divided into ticagrelor (n = 410) and clopidogrel (n 421) groups. P wave properties including P wave dispersion and atrial electromechanical conduction properties were measured as AF predictors with surface ECG and tissue Doppler imaging. Results: Baseline characteristics such as age, sex, heart rate, blood pressure, and laboratory parameters were almost the same in the ticagrelor and clopidogrel groups. The statistical analysis showed no significant difference in P wave dispersion (PWD) between ticagrelor and clopidogrel groups (40.98 +/- 12 ms versus 40.06 +/- 12 ms, P = 0.304). Subgroups analysis according to ACS types also showed no significant difference in PWD (NSTEMI: 41.16 +/- 13.8 ins versus 40.76 +/- 13.55 ms, P = 0.799; STEMI: 40.9 +/- 12.62 ins versus 39.19 +/- 11.18 ms, P = 0.132). In addition, we did not find significant difference in atrial electromechanical delay (EMD) with tissue Doppler imaging (interatrial EMD 24.11 +/- 3.06 ins versus 24.46 +/- 3.23 ms, P = 0.279). Conclusion: In conclusion, we did not find any difference in detailed electrocardiographic and echocardiographic parameters as AF predictors between ticagrelor and clopidogrel groups in patients with ACS.
1 February 2023 in Biomarkers in Medicine
Aim: To appraise the prediction of tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (SPAP) with regard to hospitalization and the effect of spironolactone use. ...
12 March 2026 in Angiology
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with lower atrial fibrillation (AF) incidence in diabetes mellitus (DM). Atrial electromechanical delay (AEMD) is an electrophysiological marker related to AF development. This study evaluated AEMD changes in type 2 DM patients treated with an SGLT2 inhibitor (dapagliflozin or empagliflozin). Baseline and 4-month follow-up data of 50 patients with type 2 diabetes who initiated SGLT2 inhibitor therapy were retrospectively obtained from medical records and analyzed. AEMD was measured using echocardiography and tissue Doppler. Inter-AEMD and intra-AEMD intervals were calculated. Left atrial volume (LAVOL) significantly decreased (45.23 ± 9.27 vs 42.21 ± 9.16; P < .001), while left intra-AEMD (19.58 ± 7.53 vs 16.76 ± 7.53; P <.001), right intra-AEMD (14.42 ± 5.81 vs 12.46 ± 8.05; P = .016), and inter-AEMD (34 ± 9.41 vs 29.22 ± 9.44; P < .001) were significantly reduced. Inter-AEMD change correlated with LAVOL, E/E′ ratio, body mass index, and mean blood pressure changes (all P <.05). In diabetic patients treated with SGLT2 inhibitors, AEMD reduction was observed after 4 months, with favorable metabolic and hemodynamic effects. These findings suggest that SGLT2 inhibitors may protect against AF by improving atrial electromechanical function.
23 November 2022 in Arquivos Brasileiros de Cardiologia
Resumo Fundamento: As matrizes metaloproteinases (MMPs) podem afetar o volume extracelular (VEC) e seus compartimentos, e isso pode oferecer informações mais detalhadas sobre o mecanismo de remodelação adversa (RA) do ventrículo esquerdo (VE) após o infarto agudo do miocárdio (IM). Objetivos: Investigar o papel que as alterações (Δ) nos compartimentos de VEC (volume matriz (MVi) e volume celular (CVi)) desempenham no desenvolvimento de RA após o IM, e sua relação com as expressões de MMP-2. Métodos: Um total de noventa [...] Resumo Fundamento: As matrizes metaloproteinases (MMPs) podem afetar o volume extracelular (VEC) e seus compartimentos, e isso pode oferecer informações mais detalhadas sobre o mecanismo de remodelação adversa (RA) do ventrículo esquerdo (VE) após o infarto agudo do miocárdio (IM). Objetivos: Investigar o papel que as alterações (Δ) nos compartimentos de VEC (volume matriz (MVi) e volume celular (CVi)) desempenham no desenvolvimento de RA após o IM, e sua relação com as expressões de MMP-2. Métodos: Um total de noventa
7 October 2026 in Angiology
Contrast-associated acute kidney injury (CA-AKI) is a serious complication associated with increased morbidity and mortality in patients with acute coronary syndrome (ACS) undergoing coronary angiography. The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel biomarker reflecting inflammatory and nutritional status. This retrospective study evaluated the prognostic value of the CALLY index calculated at hospital admission for predicting CA-AKI in 1516 patients with ACS. CA-AKI developed in 267 patients (17.6%). Patients who developed CA-AKI had significantly lower CALLY index values (0.35 ± 0.16 vs 0.84 ± 0.30; P < .001). In separate multivariable logistic regression analyses adjusted for baseline clinical and procedural confounders, the CALLY index emerged as an independent predictor of CA-AKI (Odds ratio [OR] 0.592 per 0.1-unit increase; 95% CI 0.525-0.668; P < .001). Receiver operating characteristic curve analysis demonstrated good discriminatory capacity for the CALLY index (Area Under the Curve [AUC] = 0.822), significantly outperforming conventional clinical scores and other inflammatory indices (DeLong test P < .001). Furthermore, adding the CALLY index to the Mehran risk score significantly improved reclassification metrics (Net Reclassification Improvement [NRI] = 14.2%, Integrated Discrimination Improvement [IDI] = 0.048; P < .001). The CALLY index serves as a simple, practical, and effective score for early CA-AKI risk stratification in ACS.
1 January 2026 in The Anatolian Journal of Cardiology
Background: Early risk stratification is essential in patients with non–ST-segment elevation myocardial infarction (NSTEMI). The Endothelial Activation and Stress Index (EASIX) reflects endothelial dysfunction and systemic stress; however, its prognostic value in NSTEMI remains unclear. This study aimed to investigate the association between EASIX and in-hospital mortality in patients with NSTEMI. Methods: This retrospective, single-center observational study included 1001 consecutive NSTEMI patients hospitalized between January 2015 and August 2025. Endothelial Activation and Stress Index was calculated at admission using lactate dehydrogenase, creatinine, and platelet count. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of in-hospital mortality. Discriminative performance was assessed using receiver operating characteristic analysis and Kaplan–Meier survival analysis. Results: In-hospital mortality occurred in 41 patients (4.1%). Non-survivors had significantly higher EASIX values than survivors (median 1.76 vs. 0.94, P < .001). In multivariable analysis, EASIX (OR 1.66, 95% CI 1.24-2.23; P = .001), GRACE score (OR 1.04, 95% CI 1.03-1.06; P < .001), and revascularization (OR 0.37, 95% CI 0.15-0.55; P = .003) remained independent predictors of in-hospital mortality. EASIX demonstrated good discriminative ability (AUC 0.770), and higher levels were associated with worse survival. Conclusion: Endothelial Activation and Stress Index is an independent and practical predictor of in-hospital mortality in NSTEMI and may aid early risk stratification using routine laboratory data.